← Leaderboards
Rujun Gong
Rhode Island Hospital
$5,500,994
Attributed
$6,130,632
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $969.1K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,130,632 · 4
By mechanism
R01$4,871,355 · 3
U01$1,259,277 · 1
Top collaborators
- Marc Tatar2 shared
Others in their field
Top investigators on “Kidney”
- Jeffrey P Krischer · University Of South Florida$540,222,210
- John M Lachin · George Washington University$155,894,464
- David M Nathan · Massachusetts Institute Of Technology$127,229,266
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$111,521,899
- David Heimbrook · Leidos Biomedical Research, Inc.$83,221,586
- Peter Scott Heeger · Case Western Reserve University$80,562,246
Research focus
KidneyPhysiologicalSignal TransductionAttenuatedPharmaceutical PreparationsAdriamycin PfsPodocyteKnock-OutPlayPathway InteractionsFunctional DisorderTherapeutic TargetIn VitroEnd Stage Renal FailureInjuryIn VivoMolecularKidney DiseasesMediatingBaseAffectEtiologyAcuteCessation Of Life
Grant awards (17)
Age remodels kidney-adrenal-heart interorgan communication$616,436
U01 · FY2025 · AG
Role of GSK3beta in diabetic kidney disease$339,900
R01 · FY2025 · DK · contact PI
Age remodels kidney-adrenal-heart interorgan communication$642,841
U01 · FY2024 · AG
Role of GSK3beta in diabetic kidney disease$326,304
R01 · FY2024 · DK · contact PI
Role of GSK3beta in diabetic kidney disease$339,900
R01 · FY2023 · DK · contact PI
Role of GSK3beta in diabetic kidney disease$339,900
R01 · FY2022 · DK · contact PI
The Melanocortinergic pathway inglomerular disease$351,936
R01 · FY2021 · DK · contact PI
The Melanocortinergic pathway inglomerular disease$351,745
R01 · FY2020 · DK · contact PI
The Melanocortinergic pathway inglomerular disease$349,658
R01 · FY2019 · DK · contact PI
The Melanocortinergic pathway inglomerular disease$349,658
R01 · FY2018 · DK · contact PI
The Melanocortinergic pathway inglomerular disease$191,226
R01 · FY2017 · DK · contact PI
The Melanocortinergic pathway inglomerular disease$164,525
R01 · FY2017 · DK · contact PI
Therapeutic targeting of GSK3beta: A novel approach for podocyte protection$345,825
R01 · FY2015 · DK · contact PI
Therapeutic targeting of GSK3beta: A novel approach for podocyte protection$345,825
R01 · FY2014 · DK · contact PI
Therapeutic targeting of GSK3beta: A novel approach for podocyte protection$333,722
R01 · FY2013 · DK · contact PI
Therapeutic targeting of GSK3beta: A novel approach for podocyte protection$345,825
R01 · FY2012 · DK · contact PI
Therapeutic targeting of GSK3beta: A novel approach for podocyte protection$395,406
R01 · FY2011 · DK · contact PI